Early versus deferred antiretroviral therapy for children older than 1 year infected with HIV (PREDICT): a multicentre, randomised, open-label trial
about
When to start antiretroviral therapy in children aged 2-5 years: a collaborative causal modelling analysis of cohort studies from southern AfricaGetting to 90-90-90 in paediatric HIV: What is needed?Novel Neuroimaging Methods to Understand How HIV Affects the BrainAntiretroviral treatment in HIV-infected infants and young children: novel issues raised by the Mississippi babyGrowth and Mortality Outcomes for Different Antiretroviral Therapy Initiation Criteria in Children Ages 1-5 Years: A Causal Modeling AnalysisComparison of adherence monitoring tools and correlation to virologic failure in a pediatric HIV clinical trialNeurodevelopmental outcomes in HIV-exposed-uninfected children versus those not exposed to HIVAssociation between age at antiretroviral therapy initiation and 24-month immune response in West-African HIV-infected childrenUsing CD4 percentage and age to optimize pediatric antiretroviral therapy initiationEarly viral suppression improves neurocognitive outcomes in HIV-infected children.Treatment initiation factors and cognitive outcome in youth with perinatally acquired HIV infectionNon-Nucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy in Perinatally HIV-Infected, Treatment-Naïve Adolescents in Asia.The long-term outcomes of antiretroviral treatment initiated with mono or dual nucleoside reverse transcriptase inhibitors in HIV-1-infected children: an Asian observational study.Brain Imaging and Neurodevelopment in HIV-uninfected Thai Children Born to HIV-infected MothersGrowth reconstitution following antiretroviral therapy and nutritional supplementation: systematic review and meta-analysis.The physical and psychological effects of HIV infection and its treatment on perinatally HIV-infected childrenSoluble CD163 and monocyte populations in response to antiretroviral therapy and in relationship with neuropsychological testing among HIV-infected children.Cognitive function and neurodevelopmental outcomes in HIV-infected Children older than 1 year of age randomized to early versus deferred antiretroviral therapy: the PREDICT neurodevelopmental studyAn Evaluation of Alternative Markers to Guide Initiation of Anti-retroviral Therapy in HIV-Infected Children in Settings where CD4 Assays are not AvailableImmunology of pediatric HIV infectionImpact of antiretroviral therapy on quality of life in HIV-infected Southeast Asian children in the PREDICT studyImmediate antiretroviral therapy in young HIV-infected children: benefits and risks.Neurologic disease in HIV-infected children and the impact of combination antiretroviral therapy.Tackling virological failure in HIV-infected children living in Africa.Universal antiretroviral therapy for HIV-infected children: a review of the benefits and risks to consider during implementation.The role of neuropsychology in UK pediatric HIV care: Relevance to clinical practice and research.Antiretroviral Therapy in Children Less Than 24 Months of Age at Pediatric HIV Centers in Tanzania: 12-Month Clinical Outcomes and Survival.Survival of HIV-1 vertically infected children.Reporting of pre-enrolment screening with randomized clinical trials: A small item that could impact a big difference.Brain and Cognitive Development Among U.S. Youth With Perinatally Acquired Human Immunodeficiency Virus Infection.Optimal timing of antiretroviral treatment initiation in HIV-positive children and adolescents: a multiregional analysis from Southern Africa, West Africa and Europe.Paediatric European Network for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV-1 infection 2015: optimizing health in preparation for adult life.Growth Patterns of HIV Infected Indian Children in Response to ART: A Clinic Based Cohort Study.Targeting 90-90-90--don't leave children and adolescents behind.Structural Neuroimaging and Neuropsychologic Signatures of Vertically Acquired HIV.Higher retention and viral suppression with adolescent-focused HIV clinic in South AfricaCognition, emotional health, and immunological markers in children with long-term nonprogressive HIV.Immune activation despite preserved CD4 T cells in perinatally HIV-infected children and adolescents.Advances in Pediatric Pharmacology, Therapeutics, and Toxicology.Optimizing Clinical Trial Design to Maximize Evidence Generation in Pediatric HIV
P2860
Q28535251-7929F91F-9386-4762-A218-1A7333F2790CQ30385352-CB48327D-329A-4198-B78F-65ECC9095708Q30938624-A146765D-B603-46CD-A7CA-46E1029DF113Q33557037-1858A812-CFB5-4E12-AECD-62E3815086A6Q33619587-7D2DDCF1-72B2-4D94-AA4F-8506BFD369B0Q33713856-728F22E6-EE4A-4DB3-8641-14D3D95617E1Q34005836-DE39ED12-BA5B-4318-B330-927BAEBCA551Q34214526-9AF8E166-C6D1-488D-8F99-E22BF45477C7Q34263117-E49FD02A-DC37-468E-905D-86319ED4824BQ35095168-0FF6A8C4-2E7A-4C56-97C5-67ED72C5F5FEQ35772799-F24D77D5-31E1-42A7-AC90-5149C46AA6AEQ35902391-33E516DF-5275-4432-AEBC-D0587BB2C540Q35989364-2575423A-86B3-4EAE-BAC1-D8B77E1A2354Q36073155-A2A4DCA2-55BE-45E8-9FED-091D74D4A99BQ36084809-F426A69C-F5E0-4489-8F99-B0AE270DFE2EQ36349683-DA335FA9-77BA-4F75-8282-76411539849EQ36509571-32754B33-A1A1-4547-9292-7D4BFBF26B36Q36876216-D8029731-28D2-420F-B8F3-E33D82FB7BDEQ37072466-FA7B19A9-10BD-4BF9-BA81-FF4EE585C878Q37080573-225F3DFD-8CF9-4434-8AEC-152E74A81943Q37287031-90F9DB17-632A-49FB-A04A-43252551936FQ37403284-6D38EB15-B0BA-48FA-BE79-507E1F315170Q38210096-B0CD6440-A7D4-4C63-BD58-440140AC767DQ38552894-CEB4D065-108F-4228-9BFE-636BF6355AB4Q38660444-88EE97C7-0E9C-4CEF-B710-78863836C758Q38841035-5AA228F9-8525-4687-8576-8B407C4B483CQ38844460-F55E21C0-F509-49F8-A6BD-D42DA88B931CQ38975088-90CB7FB8-0222-4B44-AA28-6C49B949E541Q38979133-83AB0467-7CFC-46FE-B74A-E83ECA658A8AQ40447366-2E207406-4FF4-4AFE-840A-22955AE906FEQ40637530-580640A9-30B1-4FFF-8AEE-9240AC1503BAQ41505058-7F80BA04-19B3-4424-849A-FA1BA32FB697Q41552413-18EF9B7F-109C-4B4E-8353-B85D7A6C9FE1Q43142354-DDA879B3-1FEB-47DA-8C3D-5E5AB7E68867Q46240366-D5BEDD03-E89A-41EF-B3A0-64085CFD3F07Q47008725-F184F8B9-9AA7-4B45-A991-E76F7928835DQ47558623-D12037D3-BB79-41A0-89B1-31D33AA87166Q48330936-63FA22AD-07A9-4C13-BF6C-D7473AB25F81Q54194778-BD46F70B-EE4D-4E1D-A619-80F3910EA411Q56910418-25C56461-5922-424E-8E40-815802E99279
P2860
Early versus deferred antiretroviral therapy for children older than 1 year infected with HIV (PREDICT): a multicentre, randomised, open-label trial
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Early versus deferred antiretr ...... , randomised, open-label trial
@ast
Early versus deferred antiretr ...... , randomised, open-label trial
@en
type
label
Early versus deferred antiretr ...... , randomised, open-label trial
@ast
Early versus deferred antiretr ...... , randomised, open-label trial
@en
prefLabel
Early versus deferred antiretr ...... , randomised, open-label trial
@ast
Early versus deferred antiretr ...... , randomised, open-label trial
@en
P2093
P2860
P50
P1476
Early versus deferred antiretr ...... , randomised, open-label trial
@en
P2093
Chaiwat Ngampiyaskul
David A Cooper
Jurai Wongsawat
Kea Chettra
Lawrence Fox
Matthew G Law
Mean Chhi Vun
PREDICT Study Group
Pope Kosalaraksa
Praphan Phanuphak
P2860
P304
P356
10.1016/S1473-3099(12)70242-6
P50
P577
2012-10-09T00:00:00Z